autologous ACTR T cells (National University Hospital)

Autologous ACTR T cells are a cell-based immunotherapy consisting of a patient's own T cells engineered to express an Antibody-Coupled T-cell Receptor (ACTR). Developed at the National University Hospital, Singapore, this specific construct utilizes the high-affinity V158 variant of the extracellular domain of CD16 (FCGR3A) linked to 4-1BB (CD137) co-stimulatory and CD3ζ signaling domains. Unlike traditional CAR-T cells that target a specific surface antigen directly, ACTR T cells are designed to bind the Fc region of a co-administered monoclonal antibody, such as rituximab. This mechanism allows the engineered T cells to mediate antibody-dependent cellular cytotoxicity (ADCC) against tumor cells coated with the antibody. In clinical trials (notably the ATTCK-20 study), these cells were administered in combination with rituximab and low-dose interleukin-2 (IL-2) for the treatment of relapsed or refractory CD20-positive B-cell malignancies, including chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). The technology was later licensed and further developed as ACTR087 and ACTR707 by Unum Therapeutics.

Other names

CD16V-BB-z T cellsCD-16V-BB-z T cellsCD 16V-BB-z T cellsCD16-4-1BB-CD3zeta engineered T cellsCD-16-4-1BB-CD3zeta engineered T cellsCD 16-4-1BB-CD3zeta engineered T cellsAntibody-Coupled T-cell Receptor T cells